

# Recro to Present at Stephens Annual Investment Conference

## Fireside Chat Webcast Available

SAN DIEGO and GAINESVILLE, Ga., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that its chief executive officer, David Enloe, will participate in a fireside chat as part of the Stephens Annual Investment Conference | NASH2021. Details for the fireside chat are as follows:

- **Stephens Annual Investment Conference | NASH2021**
  - **Conference dates:** December 1 - 3, 2021
  - **Presentation details:** Recro management will participate in a fireside chat on Friday, December 3, 2021 at 11:00 – 11:45am CT/12:00 – 12:45pm ET. The company will also host 1-on-1 meetings with investors on Friday, December 3, 2021
  - **Location:** Omni Nashville Hotel, Nashville, TN
  - **Webcast:** A live audio webcast of the fireside chat will be available under "Events" in the Investors section of the company's website, <https://ir.recropharma.com/events>. An archived webcast will be available on the company's website approximately two hours after the event and will be available for 30 days.

## About Recro

Recro (NASD: REPH) is a bi-coastal contract development and manufacturing organization (CDMO) with capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus in the area of small molecules. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market.

In addition to our experience in handling DEA controlled substances and developing and manufacturing modified-release dosage forms, Recro has the expertise to deliver on our clients' pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 145,000 square feet, in Gainesville, Georgia and San Diego, California.

For more information about Recro's CDMO solutions, visit [recrocdmo.com](http://recrocdmo.com).

Contacts

Stephanie Diaz (Investors)  
Vida Strategic Partners  
(415) 675-7401  
[sdiaz@vidasp.com](mailto:sdiaz@vidasp.com)

Tim Brons (Media)  
Vida Strategic Partners  
(415) 675-7402  
[tbrons@vidasp.com](mailto:tbrons@vidasp.com)

Ryan D. Lake (CFO)  
Recro  
(770) 531-8365  
[ryan.lake@recroCDMO.com](mailto:ryan.lake@recroCDMO.com)



Source: Recro Pharma, Inc.